A Phase 1/2 interventional study of MDX2003 in Lymphoma, Waldenström Macroglobulinemia (WM) and DLBCL - Diffuse Large B Cell Lymphoma, sponsored by ModeX Therapeutics, An OPKO Health Company. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by ModeX Therapeutics, An OPKO Health Company (part of OPKO Health, Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Lymphoma, Follicular with a site in Israel — 9 open to participants now, 22 under way, 9 of them phase 3. Lymphoma, Follicular · Israel.
Among the 51 studies in Lymphoma, Follicular with a site in Israel, this one is the 29th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 9 of the 21 other live ones, and was the 48th registered.
1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →9 of the 51 studies in Lymphoma, Follicular with a site in Israel are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Israel, United States, Argentina and 11 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Israel, United States, Argentina and 13 more countries
Ages 18+
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
AbbVie · Sites in Israel, Argentina, Australia and 10 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Israel, United States, Australia and 15 more countries
Ages 18+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 24
First in 1997; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 250 across the 48 interventional studies, 700 across the 3 observational. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModeX Therapeutics, An OPKO Health Company, one of the names counted as OPKO Health, Inc.. Under that name alone:
ModeX Therapeutics, An OPKO Health Company is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
OPKO Health, Inc. has 1 study filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
6 of the studies in Lymphoma, Follicular with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT06667687AbbVieStudy to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | 2027-01 |
| NCT07596186Soroka University Medical CenterPredict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices | 2027-01-01 |
| NCT05735704JaxBio LtdEarly Detection and Screening of Hematological Malignancies - SANGUINE | 2027-01-31 |
| NCT05512390AbbVieA Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Lymphoma, Follicular with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
This study's planned enrollment of 180 is above the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.
Browse Lymphoma, Follicular studies →ModeX Therapeutics, An OPKO Health Company is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
First submitted after ModeX Therapeutics became part of OPKO Health, Inc..
Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with B-cell malignancies will receive MDX2003 as an intravenous (IV) infusion.
Drug: MDX2003
Participants with select B-cell malignancies will receive MDX2003 as an intravenous (IV) infusion.
Drug: MDX2003
MDX2003 intravenous infusion
Part A only- Identify the Maximum Tolerated Dose (MTD) for expansion for further development of MDX2003
Maximum Tolerated Dose is determined following the evaluation of MDX2003 safety, including the incidences of dose-limiting toxicities (DLTs), MDX2003 anti-tumor activity, and MDX2003 pharmacokinetics/pharmacodynamics.
Time frame: 28 days
All Study Parts: Adverse Events (AEs)
Incidence and severity of adverse events (AEs) and serious AEs (SAEs), including changes in clinical laboratory parameters, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria, including changes in clinical laboratory parameters.
Time frame: Baseline until 90 days after the participant has the last dose of MDX2003
Part B only- Assess the preliminary anti-lymphoma activity of MDX2003
Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per Lugano Classification.
Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
All Study Parts: Measure of terminal half-life (t1/2) of MDX2003
Characterize pharmacokinetic (PK) parameter t1/2 after intravenous infusion of MDX2003.
Time frame: 6 months
All Study Parts: Measure of area under the serum concentration-time curve (AUC) of MDX2003
Characterize pharmacokinetic (PK) parameter AUC after intravenous infusion of MDX2003.
Time frame: 6 months
All Study Parts: Measure of time to maximum concentration (Tmax) of MDX2003
Characterize pharmacokinetic (PK) parameter Tmax after intravenous infusion of MDX2003.
Time frame: 6 months
All Study Parts: Measure of maximum serum concentration (Cmax) of MDX2003
Characterize pharmacokinetic (PK) parameter Cmax after intravenous infusion of MDX2003.
Time frame: 6 months
All Study Parts: Measure of volume of distribution (Vd) of MDX2003
Characterize pharmacokinetic (PK) parameter Vd after intravenous infusion of MDX2003.
Time frame: 6 months
All Study Parts: Measure of system clearance of MDX2003
Characterize pharmacokinetic (PK) parameter of system clearance after intravenous infusion of MDX2003.
Time frame: 6 months
All Study Parts: Evaluation of MDX2003 immunogenicity
The presence and persistence of anti-MDX2003 antibodies.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.
Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's planned 21 months is below that.
Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ModeX Therapeutics, An OPKO Health Company →